Accès gratuit
| Numéro |
Biologie Aujourd'hui
Volume 212, Numéro 3-4, 2018
|
|
|---|---|---|
| Page(s) | 85 - 87 | |
| DOI | https://doi.org/10.1051/jbio/2018027 | |
| Publié en ligne | 11 avril 2019 | |
- Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., Blanc, J.F., Bolondi, L., Klümpen, H.J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu, M.H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., Kelley, R.K. (2018a). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med, 379, 54-63. [CrossRef] [PubMed] [Google Scholar]
- Abou-Alfa, G.K., Chan, S.L., Furuse, J., Galle, P.R., Kelley, R.K, Qin, S., Armstrong, J., Darilay, A., Vlahovic, G., Negro, A., Sangro, B. (2018b). A randomized, multicenter phase 3 study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma: HIMALAYA study. J Clin Oncol, 36 (ASCO 2018 ; suppl ; abstr TPS4144). [Google Scholar]
- Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., Gerolami, R., Masi, G., Ross, P.J., Song, T., Bronowicki, J.P., Ollivier-Hourmand, I., Kudo, M., Cheng, A.L., Llovet, J.M., Finn, R.S., LeBerre, M.A., Baumhauer, A., Meinhardt, G., Han, G. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389, 56-66. [Google Scholar]
- El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.H., Dastani, H.B., Melero, I. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 389, 2492-2502. [CrossRef] [PubMed] [Google Scholar]
- Ikeda, M., Sung M.W., Kudo, M., Kobayashi, M., Baron, A.D., Finn, R.S., Kaneko, S., Zhu, A.X., Kubota, T., Kraljevic, S., Ishikawa, K., Siegel, A.B., Kumada, H., Okusaka, T. (2018). A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol, 36, Suppl 15, 4076 [Google Scholar]
- Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., Blanc, J.F., Vogel, A., Komov, D., Evans, T.R.J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M., Cheng, A.L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet, 391, 1163-1173. [CrossRef] [PubMed] [Google Scholar]
- Pishvaian, M.J., Lee, M.S., Ryoo, B.Y., Stein, S., Lee, K.H., Verret, W., Spahn, J., Shao, H., Liu, B., Iizuka, K., Hsu, C.H. (2018). Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol, 29, Suppl 8, LBA 26. [Google Scholar]
- Qin, S.K., Ren, Z.G., Meng, Z.Q., Chen, Z.D., Chai, X.L., Xiong, J.P., Bai, Y.X., Yang, L., Zhu, H., Fang, W.J., Lin, X.Y., Chen, X.M., Li, E.X., Xia, Y., Zou, J.J. (2018). A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma who failed or intolerable to prior systemic treatment. Ann Oncol, 29, Suppl 8, LBA 27. [Google Scholar]
- Zhu, A.X., Park, J.O., Ryoo, B.Y., Yen, C.J., Poon, R., Pastorelli, D., Blanc, J.F., Chung, H.C., Baron, A.D., Pfiffer, T.E., Okusaka, T., Kubackova, K., Trojan, J., Sastre, J., Chau I., Chang, S.C., Abada, P.B., Yang, L., Schwartz, J.D., Kudo, M. (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol, 16, 859-870. [CrossRef] [PubMed] [Google Scholar]
- Zhu, A.X., Baron, A.D., Malfertheiner, P., Kudo, M., Kawazoe, S., Pezet, D., Weissinger, F., Brandi, G., Barone, C.A., Okusaka, T., Wada, Y., Park, J.O., Ryoo, B.Y., Cho, J.Y., Chung, H.C., Li, C.P., Yen, C.J., Lee, K.D., Chang, S.C., Yang, L., Abada, P.B., Chau, I. (2017). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH trial results by Child-Pugh Score. JAMA Oncol, 3, 235-243. [Google Scholar]
- Zhu, A.X., Finn, R.S., Galle, P.R., Llovet, J.M., Blanc, J.F., Okusaka, T., Chau, I., Cella, D., Girvan, A., Gable, J., Bowman, L., Hsu, P., Abada, B., Kudo M. (2018a). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). Ann Oncol, 29(8). [Google Scholar]
- Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S.L., Knox, J., Daniele, B., Webber, A.L., Ebbinghaus, S.W., Ma, J., Siegel, A.B., Cheng, A.L., Kudo, M. (2018b). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol, 19, 940-952. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.